Navigation Links
PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
Date:9/24/2008

reated with non-pegylated rBChE supports the conclusions of an earlier study (Mikler et al, 2007) that rBChE has potential utility as a post poisoning therapy. The investigators suggest that the data provide the first tangible evidence of the predicted mechanisms of post poisoning intervention with rBChE.

"The majority of our research to date for Protexia(R) has focused on studying its efficacy as a pre-exposure prophylactic. The promising preliminary data are particularly encouraging as they demonstrate that the non-pegylated rBChE may also be efficacious as a therapeutic for nerve agents. We plan to undertake further confirmatory work with Protexia(R) to build upon these exciting preliminary observations," said Mr. Wright.

Valortim(R) Findings Reported

In a poster entitled, "Efficacy of Intravenous Valortim(R), an Anti-toxin Monoclonal Antibody, in the Treatment of Inhalation Anthrax in the African Green Monkey Model," investigators at USAMRIID sought to refine the AGM as a therapeutic model by assessing the efficacy of an anti-toxin monoclonal antibody. In the study, 21 adult AGMs were exposed by aerosol to Ames anthrax spores and blood samples were collected every 4-8 hours beginning 24-hours post exposure to assess anthrax bacteremia and protective antigen in blood. Samples were analyzed for protective antigen via a rapid electrochemiluminescent immunoassay (ECL) and bacteremia was evaluated by 24-hour culture. In the study, 6 AGMs were treated with one intravenous dose of 10 mg/kg Valortim(R) when positive by ECL; a second cohort of 6 AGMs was treated with 2 intravenous doses of 10 mg/kg Valortim(R) (the first given when positive by ECL and the second dose administered 24 hours later), and a third cohort of 6 AGMs was treated with one intravenous dose of 20 mg/kg Valortim(R) when positive by ECL.

Results showed that 56% (10 of 18) of the Valortim(R)-treated animals survived while all saline-treated controls (3) succumbed to inhalati
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
2. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
5. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 Does your doctor know what ... doctors have recommended marijuana to the over 112,000 currently registered ... the majority of the other roughly 20,300+ active physicians listed ... little about it – even though a poll in February ... say they have tried it. "With marijuana ...
(Date:8/29/2014)... 2014 Diseases largely eradicated in ... returning. Measles was declared eliminated in 2000, yet the ... August 15—the highest incidence in 20 years. In July, ... whooping cough a problem of "epidemic proportions." ... dying from these preventable diseases—in part because some parents ...
(Date:8/29/2014)... UNION CITY, Calif. , Aug. 29, 2014 /PRNewswire/ ... products company manufacturing point-of-care blood instrumentation and consumables to ... Clint Severson , Chairman and Chief Executive Officer, ... Annual Best Ideas Conference 2014 on Tuesday, September 9, ... held at the Omni Berkshire Place Hotel in ...
Breaking Medicine Technology:Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2
... Tenn., April 10 Leading RSV,investigator Dr. John DeVincenzo ... disease that causes bronchiolitis and pneumonia,according to the Centers ... the leading cause of hospitalization of infants in the ... in this age group., DeVincenzo is using the ...
... and drug development and clinical trial, ... BEDMINSTER, N.J., April 9, 2008 Clinsys ... research,organization (CRO), today introduced its Therapeutically-aligned Program,Strategists ... and execution,of clinical trials. The TPS teams ...
Cached Medicine Technology:RSV Researcher Makes Gains in Finding Treatments 2Clinsys(R) TPS Teams Provide Comprehensive Clinical Development Plans 2Clinsys(R) TPS Teams Provide Comprehensive Clinical Development Plans 3
(Date:9/1/2014)... regular family meals may help protect teens from the ... suggests. Online abuse can lead to depression, anxiety ... five adolescents experience cyberbullying," Frank Elgar, a professor at ... University in Montreal, said in a university news release. ... and abuse are difficult for parents and educators to ...
(Date:9/1/2014)... HealthDay Reporter SATURDAY, Aug. ... an experimental drug was more effective than standard treatment ... According to the study authors, the trial was ... new drug, dubbed LCZ696. In the trial, ... (Vasotec), either died or were hospitalized due to heart ...
(Date:9/1/2014)... 2014 Currently, scientists continue to ... for Alzheimer's disease (AD), which reflects their poor ... the diagnosis of the disease, especially in its ... diagnostic tests. In 2014, after decades that ... in the medicine world, there are still no ...
(Date:9/1/2014)... The B-cell non-Hodgkin’s Lymphoma (NHL) treatment market ... (the US, France, Italy, Germany, Spain and the UK), ... 2018. , The competitive landscape in the B-cell NHL ... the UK is poised to undergo a dramatic shift ... largest B-cell NHL indications, which includes Diffuse Large B-Cell ...
(Date:9/1/2014)... 2014 As well as having completed ... currently pursuing counselor certification in Louisiana. , ... CPI training program as well as the Counselor ... both personally and professionally. I am not only ... able to do so. As a Non Violent ...
Breaking Medicine News(10 mins):Health News:Family Meals May Defuse Cyberbullying's Impact, Study Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Narconon Louisiana Announces New Certifications For Staff 2
... Medical Corporation,(CRM:TSX-V) announced today that it has opened a ... Center is the Company,s first in the,state of New ... targeted for,expansion. The opening of this location represents the ... number of Centers to 14., According to the ...
... (IDF) BRIDGES translational research grant program will fund a ... for people at high-risk for getting type 2 diabetes ... develop a healthy lifestyle. , The National Hospital of ... Vietnam. Using diabetes risks questionnaires (1) , the investigators ...
... Gerson Lehrman Group, the world,s,leading marketplace for expertise, ... devoted to providing patients with the,medication information they ... personalized iGuard Risk Ratings, iGuard Safety Alerts,and a ... other registered,users who also want to get informed, ...
... is a chief reason that,patients seek medical attention; ... Physicians must be able to determine which opioid,treatment ... To make clinicians aware of the importance ... Current Clinical Practice and The,Journal of Family Practice: ...
... help breast cancer patients and menopausal women, study finds ... of a local anesthetic into the nerves of the ... long-term relief from hot flashes and sleep deprivation, a ... treatment for breast cancer, especially among women taking anti-estrogen ...
... INC. (Nasdaq:,PDEX) invites shareholders and investors to listen to ... financial results, and a discussion,of the outlook for the ... broadcast live over the Internet on,Thursday, May 15, 2008 ... by,visiting the Company,s website at http://www.pro-dex.com . Mark ...
Cached Medicine News:Health News:CRH Medical Corporation opens Center in New York 2Health News:International Diabetes Federation gives grant to diabetes screening & prevention program in Vietnam 2Health News:Gerson Lehrman Group and iGuard, Inc. Partner to Offer Patients a Voice in Healthcare Industry Decisions 2Health News:Gerson Lehrman Group and iGuard, Inc. Partner to Offer Patients a Voice in Healthcare Industry Decisions 3Health News:Treat Your Patients' Pain Effectively 2Health News:Hot Flashes Reduced by Neck Injection 2Health News:Hot Flashes Reduced by Neck Injection 3Health News:Pro-Dex, Inc. Announces Fiscal 2008 Third Quarter Financial Results Conference Call and Webcast 2
Indications For Usage: ,Used to automatically maintain a low intracuff pressure during long-term intubations....
Indications For Usage: ,Microlaryngeal surgery....
... Indications For Usage: ... ,The monitoring lumen is ... of tracheal gases especially end-tidal ... pressure. , Introducing medication. ...
... onset of VAP. (Valles J, Artigas A, ... subglottic secretions in preventing ventilator-associated pneumonia. Ann ... Auboyer C, Jospe R, et al: Prevention ... role of mechanical subglottic secretions drainage and ...
Medicine Products: